指南与共识乳腺乳腺X线

美国放射学会与乳腺影像学会更新的平均风险所有女性乳腺癌筛查推荐

Breast Cancer Screening Recommendations Inclusive of All Women at Average Risk: Update from the ACR and Society of Breast Imaging.
指南 / 共识 · J Am Coll Radiol · 2021-06-19

美国放射学会与乳腺影像学会发布更新推荐:对所有平均风险女性从40岁开始每年行乳腺X线摄影筛查,并持续至74岁以上、无严重合并症限制预期寿命时不设年龄上限,该方案死亡降低幅度最大、分期更早且间期癌更少。

要点

  • 推荐平均风险女性从40岁开始每年乳腺X线摄影筛查,不设年龄上限(严重合并症限制预期寿命者除外)。
  • 每年筛查较更长间隔筛查可检出更多筛查发现肿瘤、更小肿瘤和更少间期癌。
  • 筛查获益需与召回额外影像、良性活检及焦虑和过度诊断的可能风险一并考虑。

核心结论

  • 美国放射学会与乳腺影像学会推荐从40岁开始每年乳腺X线摄影筛查,该方案死亡降低幅度最大、诊断分期更早、手术选择更好且化疗更有效。
  • 将筛查推迟至45岁或50岁会造成不必要的乳腺癌死亡,尤其对少数族裔女性不利。
  • 筛查应持续至74岁以上,除非严重合并症限制预期寿命,否则不设年龄上限。

研究设计与样本

  • 美国放射学会与乳腺影像学会发布的乳腺癌筛查推荐更新。
  • 推荐对象为所有平均风险女性。
  • 推荐检查方法为乳腺X线摄影筛查。

诊断标准与关键数值

  • 推荐从40岁开始每年行乳腺X线摄影筛查。
  • 定期筛查可实现40%的死亡降低。
  • 年度筛查较更长筛查间隔可检出更多筛查发现肿瘤、更小肿瘤和更少间期癌。
  • 40多岁接受筛查的女性较未筛查女性更可能有早期病变、阴性淋巴结和更小肿瘤。

临床应用与阅片要点

  • 美国放射学会与乳腺影像学会推荐从40岁开始每年乳腺X线摄影筛查,并持续至74岁以上、不设年龄上限(严重合并症限制预期寿命者除外)。
  • 筛查获益应与召回额外影像、良性活检及焦虑和过度诊断的可能风险一并考虑。
  • 尽管更频繁筛查的召回和活检建议更高,但获得的生命年和避免的乳腺癌死亡也更多。
  • 希望最大化获益的女性应选择从40岁开始每年筛查,并不应过早停止筛查。

局限性

  • 筛查获益需与召回额外影像和良性活检的可能性以及焦虑和过度诊断等较不明确的风险一并考虑。
  • 更频繁筛查的召回和活检建议更高。
  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Breast cancer remains the most common nonskin cancer, the second leading cause of cancer deaths, and the leading cause of premature death in US women. Mammography screening has been proven effective in reducing breast cancer deaths in women age 40 years and older. A mortality reduction of 40% is possible with regular screening. Treatment advances cannot overcome the disadvantage of being diagnosed with an advanced-stage tumor. The ACR and Society of Breast Imaging recommend annual mammography screening beginning at age 40, which provides the greatest mortality reduction, diagnosis at earlier stage, better surgical options, and more effective chemotherapy. Annual screening results in more screening-detected tumors, tumors of smaller sizes, and fewer interval cancers than longer screening intervals. Screened women in their 40s are more likely to have early-stage disease, negative lymph nodes, and smaller tumors than unscreened women. Delaying screening until age 45 or 50 will result in an unnecessary loss of life to breast cancer and adversely affects minority women in particular. Screening should continue past age 74 years, without an upper age limit unless severe comorbidities limit life expectancy. Benefits of screening should be considered along with the possibilities of recall for additional imaging and benign biopsy and the less tangible risks of anxiety and overdiagnosis. Although recall and biopsy recommendations are higher with more frequent screening, so are life-years gained and breast cancer deaths averted. Women who wish to maximize benefit will choose annual screening starting at age 40 years and will not stop screening prematurely.

来源:J Am Coll Radiol,查看原文。版权归原作者所有。

引用

  1. Monticciolo DL, Malak SF, Friedewald SM, et al. Breast Cancer Screening Recommendations Inclusive of All Women at Average Risk: Update from the ACR and Society of Breast Imaging. J Am Coll Radiol. 2021. PMID: 34154984. doi:10.1016/j.jacr.2021.04.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。